Loading company
Just reported
From United Therapeutics's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$832.5M
+4.1% y/y
+6.3% q/q
Guided
—
No guide given
Actual
$5.71
-20% y/y
-21% q/q
Guided
—
No guide given
Actual
$307.8M
-21% y/y
-7.0% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Built from United Therapeutics Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes United Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade C+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of United Therapeutics Corporation’s grade history. The other 39 go back to October 2016.
